We are live on ! Find out more
NBRV

Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV

Delisted

NBRV was delisted on the 31st of July, 2023.

Back to rankings

44 hedge funds and large institutions have $46.6M invested in Nabriva Therapeutics plc Ordinary Shares Ireland in 2019 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 16 increasing their positions, 5 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

220% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 5

151% more call options, than puts

Call options by funds: $321K | Put options by funds: $128K

100% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 6

16% more funds holding

Funds holding: 38 → 44 (+6)

33% less capital invested

Capital invested by funds: $69.1M → $46.6M (-$22.6M)

Holders
44
Holders Change
+6
Holders Change %
+15.79%
% of All Funds
0.96%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
12
Increased
16
Reduced
5
Closed
6
Calls
$321K
Puts
$128K
Net Calls
+$193K
Net Calls Change
+$133K

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$3.28M
2
RSCM
Rock Springs Capital Management
Maryland
+$1.58M
3
JP Morgan Chase
JP Morgan Chase
New York
+$270K
4
Two Sigma Investments
Two Sigma Investments
New York
+$229K
5
ACM
Aisling Capital Management
New York
+$228K

Top Sellers

Rank Fund Capital Flow
1
VC
Vivo Capital
California
-$9.81M
2
NHAS
Novo Holdings A/S
Denmark
-$8.38M
3
FI
Fosun International
China
-$1.48M
4
WS
Wedbush Securities
California
-$105K
5
SAM
Sectoral Asset Management
Quebec, Canada
-$93K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$9.92M +$3.28M +5,811 +41%
O
2
OrbiMed
New York
$9.29M – – –
FM
3
Frazier Management
Washington
$8.51M – – –
RSCM
4
Rock Springs Capital Management
Maryland
$4.6M +$1.58M +2,800 +44%
ACM
5
Aisling Capital Management
New York
$3.82M +$228K +404 +6%
Renaissance Technologies
6
Renaissance Technologies
New York
$2.76M +$180K +320 +6%
Dimensional Fund Advisors
7
Dimensional Fund Advisors
Texas
$1.93M -$9.59K -17 -0.4%
JP Morgan Chase
8
JP Morgan Chase
New York
$886K +$270K +478 +37%
Susquehanna International Group
9
Susquehanna International Group
Pennsylvania
$880K -$34.4K -61 -3%
Morgan Stanley
10
Morgan Stanley
New York
$707K +$198K +351 +33%
Millennium Management
11
Millennium Management
New York
$666K +$110K +195 +17%
GIM
12
Granahan Investment Management
Massachusetts
$472K +$9.59K +17 +2%
Bank of America
13
Bank of America
North Carolina
$375K +$62.6K +111 +17%
Two Sigma Investments
14
Two Sigma Investments
New York
$203K +$229K +406 New
Wells Fargo
15
Wells Fargo
California
$179K +$45.1K +80 +29%
Commonwealth Equity Services
16
Commonwealth Equity Services
Massachusetts
$134K +$4.51K +8 +3%
Geode Capital Management
17
Geode Capital Management
Massachusetts
$125K – – –
Creative Planning
18
Creative Planning
Kansas
$112K +$126K +224 New
CCFM
19
Clear Creek Financial Management
Washington
$108K +$120K +212 New
PPA
20
Parametric Portfolio Associates
Washington
$105K +$1.13K +2 +1%
MP
21
MSD Partners
New York
$100K – – –
Barclays
22
Barclays
United Kingdom
$89K +$101K +179 New
Arrowstreet Capital
23
Arrowstreet Capital
Massachusetts
$66K +$74.5K +132 New
State Street
24
State Street
Massachusetts
$65K +$72.8K +129 New
WS
25
Wedbush Securities
California
$52K -$105K -186 -64%
1
2 3

NBRV Hedge Fund Activity: Q3 2019 in Review

44 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) for Q3 2019, worth a combined $46.6M — down 33% from $69.1M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new NBRV positions and 6 closed out — a net gain of 6 holders — while 16 added to existing stakes and 5 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $3.28M. The largest seller was Vivo Capital, exiting entirely with an estimated $9.81M sold.

  • 44 institutional investors held Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) as of Q3 2019, up from 38 in Q2 2019.
  • Funds reported $46.6M of Nabriva Therapeutics plc Ordinary Shares Ireland stock for Q3 2019, down 33% quarter-over-quarter.
  • 12 funds opened new Nabriva Therapeutics plc Ordinary Shares Ireland positions in Q3 2019 and 6 closed out, a net change of +6 holders.
  • The largest Nabriva Therapeutics plc Ordinary Shares Ireland buyer in Q3 2019 was Fidelity Investments, an estimated $3.28M added.
  • The largest Nabriva Therapeutics plc Ordinary Shares Ireland seller in Q3 2019 was Vivo Capital, an estimated $9.81M sold.

Based on aggregated 13F filings for Q3 2019.